New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR
The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) announced a partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low- and middle-income countries.
The partnership between GARDP and GDF reflects the increasing need to respond to the crisis of antimicrobial resistance (AMR) through global coordination. TB is caused by the bacterium Mycobacterium tuberculosis. Like other bacteria, it can evolve to develop resistance to available treatments, making those treatments less effective in the population at large. Currently, GDF supports access to medications for all types of TB, including multidrug-resistant and extensively drug-resistant TB; now in partnership with GARDP, it is broadening its approach to antibiotics for drug-resistant infections more generally.
Full details about the partnership are available here.
